KR20180105091A - 암 진단 및 치료 방법 - Google Patents
암 진단 및 치료 방법 Download PDFInfo
- Publication number
- KR20180105091A KR20180105091A KR1020180029879A KR20180029879A KR20180105091A KR 20180105091 A KR20180105091 A KR 20180105091A KR 1020180029879 A KR1020180029879 A KR 1020180029879A KR 20180029879 A KR20180029879 A KR 20180029879A KR 20180105091 A KR20180105091 A KR 20180105091A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- subject
- sample
- blood sample
- ctc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 33
- 201000011510 cancer Diseases 0.000 title claims abstract description 28
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims abstract description 81
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 50
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 50
- 210000004369 blood Anatomy 0.000 claims abstract description 45
- 239000008280 blood Substances 0.000 claims abstract description 45
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 208000037819 metastatic cancer Diseases 0.000 claims abstract description 14
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims abstract description 14
- 206010038111 Recurrent cancer Diseases 0.000 claims abstract description 11
- 230000000306 recurrent effect Effects 0.000 claims abstract description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 30
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 30
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 30
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 28
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 26
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 238000002271 resection Methods 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 3
- 238000010837 poor prognosis Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 210000005266 circulating tumour cell Anatomy 0.000 description 19
- 210000005259 peripheral blood Anatomy 0.000 description 12
- 239000011886 peripheral blood Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000001514 detection method Methods 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000001758 mesenteric vein Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012325 curative resection Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471083P | 2017-03-14 | 2017-03-14 | |
| US62/471,083 | 2017-03-14 | ||
| US201762584634P | 2017-11-10 | 2017-11-10 | |
| US62/584,634 | 2017-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180105091A true KR20180105091A (ko) | 2018-09-27 |
Family
ID=61868129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180029879A Withdrawn KR20180105091A (ko) | 2017-03-14 | 2018-03-14 | 암 진단 및 치료 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180267046A1 (enExample) |
| EP (1) | EP3376227B1 (enExample) |
| JP (1) | JP2018155752A (enExample) |
| KR (1) | KR20180105091A (enExample) |
| CN (1) | CN108572255B (enExample) |
| AU (1) | AU2018201819A1 (enExample) |
| CA (1) | CA2998065A1 (enExample) |
| TW (1) | TWI786095B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2738563C1 (ru) * | 2020-09-18 | 2020-12-14 | Ен Джун Чой | Способ прогноза малигнизации и ранней диагностики злокачественных опухолей |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110142068B (zh) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法 |
| CN111562375B (zh) * | 2020-04-20 | 2022-05-06 | 山东第一医科大学(山东省医学科学院) | 一种检测胃癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法 |
| CN111551718A (zh) * | 2020-04-20 | 2020-08-18 | 山东第一医科大学(山东省医学科学院) | 一种检测前列腺癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法 |
| TWI874453B (zh) * | 2020-09-17 | 2025-03-01 | 日商細胞雲股份有限公司 | 使用末稍血循環腫瘤細胞之解析的癌症治療方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010215838A1 (en) * | 2009-02-20 | 2010-08-26 | John Wayne Cancer Institute | B7-H3 antibody coupled bead assay for detection of circulating tumor cells |
| EP3207377B1 (en) * | 2014-10-15 | 2024-11-06 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
-
2018
- 2018-03-13 US US15/919,734 patent/US20180267046A1/en not_active Abandoned
- 2018-03-14 KR KR1020180029879A patent/KR20180105091A/ko not_active Withdrawn
- 2018-03-14 AU AU2018201819A patent/AU2018201819A1/en not_active Abandoned
- 2018-03-14 CN CN201810210273.7A patent/CN108572255B/zh active Active
- 2018-03-14 EP EP18161647.5A patent/EP3376227B1/en active Active
- 2018-03-14 CA CA2998065A patent/CA2998065A1/en active Pending
- 2018-03-14 TW TW107108604A patent/TWI786095B/zh active
- 2018-03-14 JP JP2018046822A patent/JP2018155752A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2738563C1 (ru) * | 2020-09-18 | 2020-12-14 | Ен Джун Чой | Способ прогноза малигнизации и ранней диагностики злокачественных опухолей |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3376227A1 (en) | 2018-09-19 |
| AU2018201819A1 (en) | 2018-10-04 |
| US20180267046A1 (en) | 2018-09-20 |
| CA2998065A1 (en) | 2018-09-14 |
| CN108572255B (zh) | 2023-05-16 |
| CN108572255A (zh) | 2018-09-25 |
| TWI786095B (zh) | 2022-12-11 |
| EP3376227B1 (en) | 2024-02-21 |
| TW201902534A (zh) | 2019-01-16 |
| EP3376227C0 (en) | 2024-02-21 |
| JP2018155752A (ja) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nicholson et al. | EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach | |
| Li et al. | Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer | |
| Cauley et al. | Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings | |
| KR20180105091A (ko) | 암 진단 및 치료 방법 | |
| EP3276353B1 (en) | Biomarker for diagnosis of extrahepatic bile duct carcinoma, intrahepatic bile duct carcinoma, or gallbladder carcinoma | |
| Brand et al. | Detection of early-stage pancreatic ductal adenocarcinoma from blood samples: results of a multiplex biomarker signature validation study | |
| WO2019156568A1 (en) | Methods for predicting treatment outcome and/or for selecting a subject suitable for immune checkpoint therapy | |
| Fassan et al. | Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach | |
| Li et al. | Liquid biopsy in lung cancer | |
| KR102561377B1 (ko) | 마커 분자를 기반으로 화학요법으로 치료되어야 하는 개체를 식별하는 방법 및 관련 용도 | |
| van der Toom et al. | Analogous detection of circulating tumor cells using the AccuCyte®—CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer | |
| WO1999044064A1 (en) | Method and compositions for differential detection of primary tumor cells and metastatic cells | |
| Sun et al. | Advances and challenges in gastric cancer testing: the role of biomarkers | |
| Lai et al. | Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer | |
| Chen et al. | Expression of decoy receptor 3 in liver tissue microarrays | |
| González et al. | Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience | |
| Zhu et al. | [Retracted] Study on PD‐L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World | |
| JP7237587B2 (ja) | マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用 | |
| Nagaiah et al. | Circulating tumor cells in the management of breast cancer | |
| CN115449551A (zh) | Tff1和tff3在肺癌骨转移早期诊断中的应用 | |
| US20250208138A1 (en) | Method of isolating and analyzing circulating tumor cells | |
| JP5140808B2 (ja) | 消化管間質腫瘍（ｇｉｓｔ）を患う患者の予後を予測するために使用する腫瘍マーカー及びキット並びにフェチンの使用方法 | |
| US11371995B2 (en) | Method for selecting individuals to be administered immune checkpoint inhibitor | |
| Hao et al. | BIOM-47. DECIPHERING GLIOBLASTOMA HETEROGENEITY: INTEGRATING MOLECULAR SIGNATURES AND GENOMIC LANDSCAPES TO PREDICT DRUG SENSITIVITY AND ADVANCE PRECISION ONCOLOGY | |
| 片岡温子 et al. | Expression Status of Serine Protease 27: A Prognostic Marker for Esophageal Squamous Cell Carcinoma Treated with Preoperative Chemotherapy/Chemoradiotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20180314 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210311 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20180314 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220428 Patent event code: PE09021S01D |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20220610 |